CytomX Therapeutics, Inc. (CTMX): Price and Financial Metrics

CytomX Therapeutics, Inc. (CTMX)

Today's Latest Price: $7.42 USD

0.11 (-1.46%)

Updated Dec 2 4:00pm

Add CTMX to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

CTMX Stock Summary

  • Of note is the ratio of CytomX Therapeutics Inc's sales and general administrative expense to its total operating expenses; merely 11.3% of US stocks have a lower such ratio.
  • The ratio of debt to operating expenses for CytomX Therapeutics Inc is higher than it is for about just 14.36% of US stocks.
  • As for revenue growth, note that CTMX's revenue has grown 52.05% over the past 12 months; that beats the revenue growth of 90.13% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CytomX Therapeutics Inc are WVE, CRBP, MTEM, PIRS, and NTLA.
  • Visit CTMX's SEC page to see the company's official filings. To visit the company's web site, go to

CTMX Stock Price Chart Interactive Chart >

Price chart for CTMX

CTMX Price/Volume Stats

Current price $7.42 52-week high $15.44
Prev. close $7.53 52-week low $3.60
Day low $7.32 Volume 616,100
Day high $7.52 Avg. volume 498,833
50-day MA $6.98 Dividend yield N/A
200-day MA $7.75 Market Cap 342.98M

CytomX Therapeutics, Inc. (CTMX) Company Bio

CytomX Therapeutics develops a novel class of antibody therapeutics based on its Probody technology platform that address clinically-validated cancer targets in immuno-oncology. The company was founded in 2008 and is based in San Francisco, California.

CTMX Latest News Stream

Event/Time News Detail
Loading, please wait...

CTMX Latest Social Stream

Loading social stream, please wait...

View Full CTMX Social Stream

Latest CTMX News From Around the Web

Below are the latest news stories about CytomX Therapeutics Inc that investors may wish to consider to help them evaluate CTMX as an investment opportunity.

CytomX Therapeutics, Inc. (CTMX) CEO Sean McCarthy on Q2 2020 Results - Earnings Call Transcript

CytomX Therapeutics, Inc. (CTMX) Q2 2020 Earnings Conference Call August 06, 2020 5:30 PM ET Company Participants Christopher Keenan – Vice President of Investor Relations Sean McCarthy – President, Chief Executive Officer and Chairman Carlos Campoy – Senior Vice President and Chief Financial Officer Conference Call Participants Waleed – Barclays...

SA Transcripts on Seeking Alpha | August 8, 2020

CytomX Therapeutics (CTMX) Earnings Expected to Grow: Should You Buy?

CytomX Therapeutics (CTMX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2020

Did Hedge Funds Make The Right Call On CytomX Therapeutics, Inc. (CTMX) ?

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]

Yahoo | July 20, 2020

CLASS ACTION UPDATE for CTMX, GEO and JCOM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACESSWIRE / July 20, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies.

Yahoo | July 20, 2020

FINAL DEADLINE TODAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against CytomX Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / July 20, 2020 / The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class-action lawsuit against CytomX Therapeutics, Inc.

Yahoo | July 20, 2020

Read More 'CTMX' Stories Here

CTMX Price Returns

1-mo 10.25%
3-mo 13.11%
6-mo -7.94%
1-year 13.98%
3-year -64.31%
5-year -68.64%
YTD -10.71%
2019 -44.97%
2018 -28.47%
2017 92.08%
2016 -47.34%
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.866 seconds.